Early clinical data demonstrate the identification of a positive KPC K. pneumoniae infection by the T2Resistance and T2Bacteria Panels, which helped to optimize therapy in just ~7 hours from specimen collection.
A 56-year-old male with acute myeloid leukemia, Crohn’s disease under corticosteroid therapy, and acute graft vs. host disease (GVHD) after bone marrow allotransplant.
First blood culture pairs and T2Bacteria sample: negative
Broad-spectrum therapy meropenem and vancomycin
After 4 days, further deterioration , qSOFA=3, WBC 790 x 109/L, PCR 12.6 mg/l, PCT 1.16 ng/ml
Rectal surveillance sample positive for KPC K. pneumoniae
Blood culture and T2Bacteria repeated, and T2Resistance collected and processed
T2Bacteria positive species ID: K. pneumoniae and T2Resistance positive for KPC; 4.5 hrs and 6.5 hrs from collection (respectively)
Therapy was optimized to ceftazidime/avibactam within 7 hours of collection
Walsh, TJ., et al. Prospective Study of the T2Resistance (T2R) System for Detection of Resistance Genes in Bacterial Bloodstream Infections. Abstracts of the European Congress for Clinical Microbiology and Infectious Diseases (ECCMID), Abstr 3434; 2021. 2019
JOIN THE MAILING LIST!
T2 BIOSYSTEMS OVERVIEW
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.